Robert Kamen, Ph.D.
“The most gratifying thing is to meet someone whose life is better because of the work you’ve done.”
At Third Rock, Bob focuses on the formation and development of biologics companies that develop life-changing therapies for patients, and he is inspired by every member of the TRV team’s willingness to take a risk in order to make a real difference for patients.
Bob has more than 35 years of leadership experience in the pharmaceutical and biotechnology industries. He previously served as president of Abbott (now AbbVie) Bioresearch Center and its predecessor BASF Bioresearch Corporation, where he oversaw the discovery and production of Humira®, the first fully human antibody product to achieve marketing approval and for many years the world’s top selling pharmaceutical. Prior to Abbot and BASF, he was SVP Scientific Affairs at Genetics Institute, a pioneering biopharmaceutical firm that was acquired by Wyeth. He currently serves as a director of Jounce, Neon, Harbour Biomed, Lycera, and Epimab Biotherapeutics.